Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Elevation Oncology, Inc.

Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are rethinking drug development by seeking out innovative, selective cancer therapies that can be matched to a patient’s unique tumor characteristics. 
 
Our lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) designed to target Claudin 18.2, a clinically validated molecular target. EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. We are working to rapidly advance EO-3021 into the clinic in the US across a range of solid tumor indications, as well as exploring other opportunities through new or existing partnerships and business development opportunities to expand our novel oncology pipeline.

K2 HealthVentures

Aisling Capital

Biotechnology Value Fund

BVF Partners

Vivo Capital

Janus Henderson Investors

venBio Partners

Cormorant Asset Management

Driehaus Capital Management

Samsara BioCapital

Qiming Venture Partners USA

Vertex Ventures HC

Elevation Oncology

Today we announced the appointment of Darcy Mootz, Ph.D., to our Board of Directors. 
 
Darcy Mootz, Ph.D., currently serves as President of Architect Therapeutics, a position she has held since April 2023. She is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations. 
 
https://lnkd.in/eztEX_eY
 
#Oncology #ADC #Innovation

In an interview with Bioprocess Online, Elevation Oncology’s CEO, Joseph Ferra, and CSO, Dr. David Dornan, shared their insights on what made EO-3021 worth licensing and how the company is executing its clinical strategy. 

Discover the factors that Elevation Oncology considered when licensing their lead ADC program, EO-3021, aimed at treating solid tumors that are likely to express Claudin 18.2.

Read the full interview by Tyler Menichiello on Bioprocess Online: https://bit.ly/3vVXK5w

#Oncology #ADC #Licensing #drugdevelopment

Senior writer Adam Feuerstein of STAT delves into Elevation Oncology's impressive market valuation surge in 2024, amidst a wave of investor interest in undervalued ADC companies. This comes as major players invest billions in ADC deals.

Discover more in Adam's insightful column (subscription required): https://bit.ly/4b9RHum

#oncology #valuation #drugdevelopment #marketvaluation

We had a wonderful and productive time at #JPM2024, meeting with other innovators in the healthcare industry to discuss what 2024 has in store and enjoying #SanFrancisco.

Great connecting and catching up with everyone! Until next year! 

#Oncology #ADC #Innovation #Biopharma

Elevation Oncology is excited to present a Trial in Progress poster for the currently enrolling Phase 1 study of EO-3021, a Claudin 18.2 ADC, today at the 2024 ASCO Gastrointestinal Cancers Symposium. 

https://lnkd.in/eJedHj-Q
 
$ELEV #ASCOGI2024 #clinicaltrial #claudin18 #ADC #drugdevelopment #cancer #oncology

Our CEO, Joseph Ferra, had a great conversation with host Matthew Pillar on Bioprocess Online’s Business of Biotech podcast, discussing our potential best-in-class #ADC candidate EO-3021 and the challenges of navigating today’s #biotech market.
 
Podcast website: https://lnkd.in/ekaGDDTV 
 
Listen on Apple podcasts: https://lnkd.in/eaderina
 
Listen on Spotify: https://lnkd.in/eaderina 
 
#Oncology #Innovation #Podcast

Today we announced program updates and upcoming #milestones including:
 
Plans to expand our clinical development program to evaluate EO-3021 in combination. We believe a combination approach has the potential to offer optimal outcomes to patients, particularly in the gastric cancer setting, with both immunotherapy and targeted agents. We expect to share details on our planned Phase 1 combination study in the first half of 2024.
 
HER3-ADC: Our second program is a differentiated HER3-targeting ADC. HER3 is a well-validated ADC target, which is overexpressed across solid tumors and often associated with poor outcomes. There are currently no HER3-targeted ADC agents approved for the treatment of cancer. We’re currently evaluating our HER3-ADC program and plan to nominate a development candidate in 2024.
 
https://lnkd.in/exKQWcXG 
 
#Oncology #Biotech #ADC #Innovation

Wishing a very happy and restful holiday season to our colleagues, partners and the patient communities we aim to serve. We are grateful for your contributions and collaboration. 

Looking forward to 2024!

#HappyHolidays #HappyNewYear #Oncology #Biotech

We had a great time at our in-person meeting in Austin, TX, in November. It was wonderful spending time with everyone, celebrating milestones, and meeting new team members.

We took this time to strategize internally through executive presentations and were excited to give back to the city of Austin by making gift bags for patients at the local children’s hospital.

Looking forward to a great 2024!

#GoTeam #GivingBack #Austin #Oncology #Biotech

November is #StomachCancerAwarenessMonth! Globally, stomach cancer is the fourth most common cancer and the second leading cause of worldwide cancer deaths. In the US alone, an estimated 26.5k new cases of stomach cancer will be diagnosed every year.
 
Learn more about stomach cancer awareness: https://lnkd.in/etQj25R4

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share		4.80 -	12.06 151.11%	3.88 67.82%	2.44 37.15%
company equity multiplier	-0.33 -	-3.51 975.60%	1.06 130.31%	1.92 80.74%	1.63 15.36%
days of inventory outstanding
days of payables outstanding					4.75K -
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit		1.00 -	1.00 0.04%	1.01 0.56%	1.13 12.63%
effective tax rate				-0.00 -	-0.00 149.74%
enterprise value multiple		-6.36 -	2.29 135.96%	-0.06 102.60%	0.02 134.15%
fixed asset turnover
free cash flow per share		-0.75 -	-2.49 232.42%	-3.68 47.91%	-1.65 55.17%
gross profit margin
interest coverage				-197.39 -	-9.68 95.10%
inventory turnover
long term debt to capitalization				0.38 -	0.35 5.42%
net income per ebt		1 -	1 0%	1.00 0.03%	1.00 0.04%
net profit margin
operating cash flow per share		-0.74 -	-2.49 234.34%	-3.67 47.76%	-1.65 55.13%
operating profit margin
payables turnover					0.08 -
pretax profit margin
price fair value		-8.20 -	0.52 106.33%	0.45 13.16%	0.33 25.94%
receivables turnover
return on assets		-0.21 -	-0.21 0.43%	-1.01 371.15%	-0.51 49.20%
return on capital employed		-0.23 -	-0.23 2.28%	-1.20 429.05%	-0.47 60.59%
return on equity		0.75 -	-0.23 130.44%	-1.94 751.56%	-0.83 57.00%
total debt to capitalization				0.38 -	0.35 5.42%

COM:ELEVATIONONCOLOGY

Elevation Oncology, Inc.

Last Close

0.61

22/11 21:00

Market Cap

34.29M

Beta: -

Volume Today

188.17K

Avg: -

Preview